An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET/CT: A Single-center, Prospective Study

被引:1
作者
Ora, Manish [1 ]
Saini, Vivek Kumar [3 ]
Dixit, Manish [1 ]
Singh, Uday Pratap [2 ]
Gambhir, Sanjay [1 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Nucl Med, Lucknow 226014, Uttar Pradesh, India
[2] Sanjay Gandhi Postgrad Inst Med Sci, Dept Urol, Lucknow, Uttar Pradesh, India
[3] All India Inst Med Sci, Dept Nucl Med, Rishikesh, Uttarakhand, India
来源
INDIAN JOURNAL OF NUCLEAR MEDICINE | 2024年 / 39卷 / 03期
关键词
Ga-68-prostate-specific membrane antigen positron emission tomography; computed tomography; Tc-99m-prostate-specific membrane antigen single photon emission computed tomography; biochemical recurrence; prostate cancer; DEFINITION; SPECT/CT; FAILURE; PSA;
D O I
10.4103/ijnm.ijnm_8_24
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective:Biochemical recurrence (BCR) after initial management of Prostate Carcinoma (PC) is frequent. Subsequent interventions rely on disease burden and metastasis distribution. Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is an excellent imaging modality in BCR. However, Ga-68 is radionuclide generator produced and has restricted availability. (99)mTc-labeled PSMA could be a potential cost-effective alternative. We compared the performance of Tc-99m-PSMA single-photon emission CT (SPECT)/CT and Ga-68-PSMA PET/CT in BCR with a serum prostate surface antigen (PSA) level of <20 ng/mL. Materials and Methods:The prospective study included 25 patients with BCR and at least one lesion on a Ga-68-PSMA PET/CT. All patients underwent 99 mTc-PSMA SPECT/CT, and disease distribution and metastatic burden were compared with Ga-68-PSMA PET/CT. The maximum standard uptake value (SUVmax) and the tumor-to-background ratio (TBR) were computed and analyzed. Results:The mean age and serum PSA (SPSA) were 69.72 6.69 years and 5.65 +/- 6.07 ng/mL. Eleven patients (44%) had SPSA <= 2 ng/mL. Recurrent sites were noted in the prostate (19, 76%), prostatic bed (3, 12%), and pelvis lymph nodes (LNs) (13, 52%). Distant metastasis to bones (13, 52%), lungs (5, 20%), and retroperitoneal LNs (2, 8%) were noted. Both modalities were concordant for the recurrent disease at the prostate, prostatic bed, bone, and lung lesions. Tc-99m-PSMA could localize pelvis LNs in most patients (10/13, 76.9%). The site-specific sensitivity and specificity between the two modalities were not significantly different (P > 0.05). TBR shows excellent correlation with SUVmax (0.783, P < 0.001). Four (16%) patients were understaged with Tc-99m-PSMA due to the nonvisualization of the subcentimeter size LNs. No patient with systemic metastases was understaged. Conclusions:Tc-99m-PSMA SPECT/CT has good concordance with Ga-68-PSMA PET/CT in BCR, even at low PSA levels. However, it may miss a few subcentimeter LNs due to lower resolution. Tc-99m-PSMA SPECT/CT could be a simple, cost-effective, and readily available imaging alternative to PET/CT.
引用
收藏
页码:170 / 176
页数:7
相关论文
共 50 条
  • [41] Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions
    Stefano Fanti
    Silvia Minozzi
    Joshua James Morigi
    Frederik Giesel
    Francesco Ceci
    Christian Uprimny
    Michael S. Hofman
    Matthias Eiber
    Sarah Schwarzenbock
    Paolo Castellucci
    Cristina Bellisario
    Stéphane Chauvie
    Fabrizio Bergesio
    Louise Emmett
    Uwe Haberkorn
    Irene Virgolini
    Markus Schwaiger
    Rodney J. Hicks
    Bernd J. Krause
    Arturo Chiti
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1622 - 1635
  • [42] Clinical value of negative68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients
    Celli, M.
    De Giorgi, U.
    Caroli, P.
    Di Lorio, V
    Fantini, L.
    Rossetti, V
    Foca, F.
    Nicolini, S.
    Giganti, M.
    Paganelli, G.
    Matteucci, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 87 - 94
  • [43] Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients
    M Celli
    U De Giorgi
    P Caroli
    V Di Iorio
    L Fantini
    V Rossetti
    F Foca
    S Nicolini
    M Giganti
    G Paganelli
    F Matteucci
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 87 - 94
  • [44] Prospective Comparison of 68 Ga-NeoB and 68 Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer
    Duan, Heying
    Song, Hong
    Davidzon, Guido A.
    Moradi, Farshad
    Liang, Tie
    Loening, Andreas
    Vasanawala, Shreyas
    Iagaru, Andrei
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (06) : 897 - 903
  • [45] Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT
    Chen, Ruohua
    Wang, Yining
    Shi, Yiping
    Zhu, Yinjie
    Xu, Lian
    Huang, Gang
    Liu, Jianjun
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (09) : 2970 - 2977
  • [46] Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT
    Caglar, Meltem
    Tuncel, Murat
    Yildiz, Egemen
    Karabulut, Erdem
    ANNALS OF NUCLEAR MEDICINE, 2020, 34 (12) : 932 - 941
  • [47] Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study
    Schollhammer, Romain
    Robert, Gregoire
    Asselineau, Julien
    Yacoub, Mokrane
    Vimont, Delphine
    Balamoutoff, Nicolas
    Bladou, Franck
    Benard, Antoine
    Hindie, Elif
    Gallerande, Henri de Clermont
    Morgat, Clement
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 379 - 385
  • [48] Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT
    Meltem Caglar
    Murat Tuncel
    Egemen Yildiz
    Erdem Karabulut
    Annals of Nuclear Medicine, 2020, 34 : 932 - 941
  • [49] 68Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis
    Wang, Rang
    Shen, Guohua
    Yang, Ruoning
    Ma, Xuelei
    Tian, Rong
    EUROPEAN JOURNAL OF RADIOLOGY, 2020, 130
  • [50] Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients
    Leon Will
    Frederik L. Giesel
    Martin T. Freitag
    Anne K. Berger
    Walter Mier
    Klaus Kopka
    Stefan A. Koerber
    Hendrik Rathke
    Christophe Kremer
    Clemens Kratochwil
    Hans-Ulrich Kauczor
    Uwe Haberkorn
    Tim F. Weber
    Cancer Imaging, 17